GlassScriptPhysician profile
Tamika A Martin
NPI 1598206294
$6,952.59
in general payments reported to CMS, 2019-2025
53 companies · $58.04 in 2025
The $58.04 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,475 · 2022: $2,090 · 2023: $2,062 · 2024: $267 · 2025: $58.04.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,293 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,293.22 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $982.02 | 2021-2024 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $841.04 | 2021-2024 | |
| Astellas Pharma US INC | $568.12 | 2021-2024 | Veozah, Myrbetriq |
| Otsuka America Pharmaceutical, INC. | $350.24 | 2021-2024 | Rexulti |
| Janssen Pharmaceuticals, INC | $277.61 | 2021-2023 | Xarelto |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $269.92 | 2021-2023 | Xifaxan, Trulance |
| Novartis Pharmaceuticals Corporation | $257.42 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $232.27 | 2021-2025 | Farxiga |
| Amgen INC. | $221.84 | 2022-2023 | Evenity, Prolia, Repatha |
| Glaxosmithkline, LLC. | $217.71 | 2021-2023 | Shingrix, Arexvy |
| Pfizer INC. | $214.57 | 2021-2023 | |
| Abbott Laboratories | $165.52 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $145.77 | 2021-2023 | |
| Amarin Pharma, INC. | $145.24 | 2021 | |
| Lilly USA, LLC | $141.65 | 2021-2023 | Emgality, Jardiance, Mounjaro |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tamika Martin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.